Ozempic Alternatives in 2026

There is no single "best" alternative — it depends on your goal, what a clinician prescribes, and your budget. For weight loss, the FDA-approved options are Wegovy (the higher-dose version of the same drug as Ozempic), Zepbound (tirzepatide), and the oral semaglutide pill. In the head-to-head SURMOUNT-5 trial, tirzepatide produced a 20.2% mean body-weight reduction at 72 weeks versus 13.7% for semaglutide. Tirzepatide-based Zepbound therefore tends to produce more weight loss, but tolerability and access differ by person. Discuss options with a licensed clinician; these are advertised estimates to verify, not medical advice.

Lower-cost FDA-approved options exist. The oral semaglutide (Wegovy) pill launched in early 2026 at about $149 per month self-pay. Novo Nordisk's NovoCare self-pay price for Ozempic and Wegovy pens is roughly $349 per month for most doses. Non-GLP-1 pills are cheaper still: Qsymia runs about $98–$250 per month, Contrave roughly $240–$480 per month, and generic phentermine $30–$50 per month — though phentermine is approved only for short-term use and produces less weight loss. Confirm current pricing with each manufacturer or pharmacy.

It is heavily restricted. The FDA declared the semaglutide and tirzepatide shortages resolved in 2025, which ended the broad exception that allowed mass compounding. On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, with a comment period that closed June 29, 2026. Patient-specific 503A compounding remains legal only in narrow cases such as a documented excipient allergy or an unavailable dose strength — routine copying of approved drugs is not allowed. Treat any "cheap compounded GLP-1" offer with caution and verify the pharmacy's licensing.

Ozempic and Wegovy are both semaglutide from Novo Nordisk: Ozempic is FDA-approved for type 2 diabetes and Wegovy for chronic weight management at a higher dose. Mounjaro and Zepbound are both tirzepatide from Eli Lilly: Mounjaro is approved for diabetes and Zepbound for weight management. Tirzepatide acts on two gut-hormone receptors (GIP and GLP-1) while semaglutide acts on one (GLP-1). Using a diabetes drug purely for weight loss is off-label; the weight-management versions are the on-label choice.

Yes. In December 2025 the FDA approved an oral semaglutide pill marketed as Wegovy (25 mg once daily) — the first oral GLP-1 approved for chronic weight management — which became available in early January 2026 at about $149 per month self-pay. Rybelsus is a separate, lower-dose oral semaglutide approved for type 2 diabetes, not weight loss. An oral form lets some people avoid injections, but it is still a prescription medication; talk to a clinician about whether it fits your situation.

Several FDA-approved pills do not use the GLP-1 mechanism: Qsymia (phentermine plus topiramate), Contrave (bupropion plus naltrexone), Xenical/Alli (orlistat), and phentermine alone. They generally produce less weight loss than GLP-1 drugs — roughly 5–10% of body weight — but cost less and suit people who cannot or prefer not to use injectables. Each has its own risk profile and candidacy; a clinician decides what is appropriate. Pricing here is an estimate to confirm with the pharmacy.